Диссертация (1140225), страница 18
Текст из файла (страница 18)
Kyle RA, Rajkumar SV. Monoclonal gammopathy of undeterminedsignificance. Br J Haematol. 2006; 134(6):573-89. doi: 10.1111/j.13652141.2006.06235.x.69. Kyle R, Rajkumar S. Monoclonal gammopathy of undetermined significanceand smouldering multiple myeloma: emphasis on risk factors for progression.116BrJHaematol.2007;139(5):730-743.doi:10.1111/j.1365-2141.2007.06873.x.70. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undeterminedsignificance and smoldering multiple myeloma. Curr Hematol Malig Rep.2010; 5(2):62-9. doi: 10.1007/s11899-010-0047-9.71. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, KrögerN, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H,Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S,Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I,Westin J, Boccadoro M; International Myeloma Working Group. Monoclonalgammopathy of undetermined significance (MGUS) and smoldering(asymptomatic) multiple myeloma: IMWG consensus perspectives riskfactors for progression and guidelines for monitoring and management.Leukemia.
2010; 24(6):1121–7. doi:10.1038/leu.2010.60.72. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB,Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV.Monoclonal gammopathy of undetermined significance (MGUS) consistentlyprecedes multiple myeloma: A prospective study. Blood.
2009; 113: 5412-7.doi: 10.1182/blood-2008-12-194241.73. Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R,Kumar SK, Dispenzieri A, Greenberg AJ, Therneau TM, Melton LJ 3rd,Caporaso N, Korde N, Roschewski M, Costello R, McQuillan GM, RajkumarSV. Racial disparities in the prevalence of monoclonal gammopathies: apopulation-based study of 12,482 persons from the National Health andNutritional Examination Survey.
Leukemia. 2014; 28(7):1537-42. doi:10.1038/leu.2014.34.74. Landgren O, Iskander K. Modern multiple myeloma therapy: deep, sustainedtreatment response and good clinical outcomes. J Intern Med. 2017; 281(4):365-382. doi: 10.1111/joim.12590.11775. Legg A, Hobbs JA, Mead GP, Bradwell AR. Monoclonal vs polyclonal freelight chain assays. Am J Clin Pathol. 2009; 131(6):901-2; author reply 902-3.doi: 10.1309/AJCPBWZD3EFWHNLL.76. Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP,Dispenzieri A, Song KW, Kyle RA; International Kidney and MonoclonalGammopathyResearchGroup.Monoclonalgammopathyofrenalsignificance: when MGUS is no longer undetermined or insignificant. Blood.2012; 120 (22): 4292-5.
doi: 10.1182/ blood-2012-07-445304.77. Markowitz GS. Dysproteinemia and the kidney. Adv Anat Pathol. 2004;11(1):49-63.78. Meltzer M, Franklin EC. Cryoglobulinemia--a study of twenty-nine patients.I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Am JMed. 1966; 40(6):828-36.79. Meri, S., Koistinen, V., Miettinen, A., Tornroth, T. G., and Seppala, I. J. T.Activation of the alternative pathaway of complement by monoclonal lambdaL chains in membranoproliferative glomerulonephritis. J.
Exp. Med. 1992;175, 939–950.80. Merlini G., Palladini G. Differential diagnosis of monoclonal gam-mopathy ofundetermined significance. Hematology. Am. Soc. Hematol. Educ. Program.2012; 2012: 595-603. doi: 10.1182/asheduca-tion-2012.1.595.81. Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB,Nadasdy T, D'Agati VD. Proliferative glomerulonephritis with monoclonalIgGdeposits.J.Am.Soc.Nephrol.2009;20:2055-64.doi:10.1681/ASN.2009010110.82. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, Nuvolone M,Obici L, Casarini S, Donadei S, Albertini R, Righetti G, Marini M, GrazianiMS, Melzi D'Eril GV, Moratti R, Merlini G. Identification of amyloidogeniclight chains requires the combination of serum-free light chain assay withimmunofixation of serum and urine.
Clin Chem. 2009; 55(3):499-504. doi:10.1373/clinchem.2008.117143.11883. Palladini G, Merlini G.The elusive pathogenesis of Schnitzler syndrome.Blood. 2018 Mar 1; 131(9):944-946. doi: 10.1182/blood-2018-01-824862.84. Parry H., Pratt G., Hutchison C. Monoclonal gammopathy of undeterminedsignificance: an update for nephrologists. Adv.
Chron. Kidney Dis. 2012; 19(5): 291-6. doi: 10.1053/j.ackd.2012.07.006.85. Pozzi C, D’Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S,Quattrocchio G, Rollino C, Segagni S, Locatelli F. Light chain depositiondisease with renal involvement: clinical characteristics and prognostic factors.Am J Kidney Dis. 2003; 42(6):1154-1163.86. Rajkumar, S. V., Kyle, R. A., Therneau, T. M., Melton, L. J., Bradwell, A. R.,Clark, R.
J., Katzmann, J. A. Serum free light chain ratio is an independentrisk factor for progression in monoclonal gammopathy of undeterminedsignificance Blood. 2005; 106: 812-817. doi: 10.1182/blood-2005-03-1038.87. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV,Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B,Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L,Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ,Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, KyleRA, Anderson KC, Durie BG, Miguel JF.
International Myeloma WorkingGroup updated criteria for the diagnosis of multiple myeloma. Lancet Oncol.2014; 15(12):e538–e548. doi: 10.1016/S1470-2045(14)70442-5.88. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, BumbeaH, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G,Morilla R, Mylin AK, Omedé P, Pellat-Deceunynck C, Perez Andres M,Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C,Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, SanMiguel JF, Sonneveld P, Johnsen HE; European Myeloma Network. Reportof the European Myeloma Network on multiparametric flow cytometry inmultiple myeloma and related disorders. Haematologica.
2008; 93(3):431-8.doi: 10.3324/haematol.11080.11989. Russell WJ, Cardelli J, Harris E, Baier RJ, HerreraGA. Monoclonal lightchain-mesangial cell interactions: early signaling events and subsequentpatholo-gic effects. Lab Invest 2001; 81:689-703.90. Said SM, Cosio FG, Valeri AM, Leung N, Sethi S, Salameh H, Cornell LD,Fidler ME, Alexander MP, Fervenza FC, Drosou ME, Zhang D, D'Agati VD,Nasr SH. Proliferative glomerulonephritis with monoclonal immunoglobulinG deposits is associated with high rate of early recurrence in the allograft.Kidney Int. 2018; 94(1):159-169. doi: 10.1016/j.kint.2018.01.028.91. Sanada S, Ookawara S, Karube H, Shindo T, Goto T, Nakamichi T, Saito M,Matsubara M, Suzuki M. Marked recovery of severe renal lesions in POEMSsyndrome with high-dose melphalan therapy supported by autologous bloodstem cell transplantation. Am J Kidney Dis.
2006, 47 (4): 672-679. doi:10.1053/j.ajkd.2006.01.004.92. Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-DureyMA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grünfeld JP,Niaudet P, Lesavre P, Frémeaux-Bacchi V. Acquired and genetic complementabnormalities play a critical role in dense deposit disease and other C3glomerulopathies. Kidney Int. 2012; 82(4):454-64. doi: 10.1038/ki.2012.63.93. Sethi S, Zand L, Leung N, Smith RJ, Jevremonic D, Herrmann SS, FervenzaFC. Membranoproliferative glomerulonephritis secondary to monoclonalgammopathy.
Clin J Am Soc Nephrol. 2010; 5(5): 770-82. doi:10.2215/CJN.06760909.94. Sethi S, Sukov WR, Zhang Y, Fervenza FC, Lager DJ, Miller DV, CornellLD, Krishnan SG, Smith RJ. Dense deposit disease associated withmonoclonal gammopathy of undetermined significance. Am J Kidney Dis.2010; 56(5):977-82. doi: 10.1053/j.ajkd.2010.06.021.95. Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD,Dogan A, Smith RJ. C3 glomerulonephritis: clinicopathological findings,complement abnormalities, glomerular proteomic profile, treatment, andfollow-up. Kidney Int. 2012; 82 (4): 465—73. doi:10.1038/ki.2012.212.12096. Sethi S, Rajkumar SV. Monoclonal gammopathy-associated proliferativeglomerulonephritis.
MayoClinProc. 2013; 88(11):1284-1293. doi:10.1016/j.mayocp.2013.08.002.97. Sethi S, Fervenza FC, Rajkumar SV. Spectrum of manifestations ofmonoclonal gammopathy-associated renal lesions. Curr Opin NephrolHypertens. 2016; 25:127-137. doi: 10.1097/MNH.0000000000000201.98. Steiner N, Göbel G, Suchecki P, Prokop W, Neuwirt H, Gunsilius E.Monoclonal gammopathy of renal significance (MGRS) increases the risk forprogression to multiple myeloma: an observational study of 2935 MGUSpatients.
Oncotarget. 2017; 9(2): 2344-2356. doi:10.18632/oncotarget.23412.99. Teng J, Russell WJ, Gu X, Cardelli J, Jones ML, Herrera GA Different typesof glomerulopathic light chains interact with mesangial cells using a commonreceptor but exhibit different intracellular trafficking patterns. Lab Invest.2004; 84(4):440-451. doi: 10.1038/labinvest.3700069.100. Waldenstrom J. Studies on conditions associated with disturbed gammaglobulin formation (gammopathies).
Harvey Lect. 1960-1961; 56: 211-231.101. Wang PX, Sanders PW. Immunoglobulin light chains generate hydrogenperoxide.JAmSocNephrol.2007;18(4):1239-45.doi:10.1681/ASN.2006111299.102. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonalgammopathy precedes multiple myeloma in most patients. Blood. 2009; 113:5418-22. doi: 10.1182/blood-2008-12-195008.103. Willrich MAV, Murray DL, Kyle RA. Laboratory testing for monoclonalgammopathies: Focus on monoclonal gammopathy of undeterminedsignificance and smoldering multiple myeloma.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
